606 results on '"Ampuero, Javier"'
Search Results
2. Liver cancer stem cell dissemination and metastasis: uncovering the role of NRCAM in hepatocellular carcinoma
3. Circulating bone morphogenetic protein 8A is a novel biomarker to predict advanced liver fibrosis
4. Crohn´s disease is an independent risk factor for liver fibrosis in patients with inflammatory bowel disease and non-alcoholic fatty liver disease
5. Neuroblastoma RAS viral oncogene homolog (N-RAS) deficiency aggravates liver injury and fibrosis
6. Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis
7. Proceedings of the 5th Meeting of Translational Hepatology, organized by the Spanish Association for the Study of the Liver (AEEH)
8. Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosis
9. An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography
10. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis
11. FRI-171 Paediatric solid organ transplant recipients (SOTR) demonstrate greater serological response to initial SARS-CoV-2 vaccination than adult SOTR, and comparable rates of antibody degradation
12. WED-172 Transaminase Pattern Over Time Is Not Associated with a More Aggressive Hepatic Evolution: Results from the AEEH Wilson Registry
13. FRI-501 Platelet-derived extracellular vesicles (PEVs) as a potential biomarker for hepatocellular carcinoma (HCC)
14. THU-287 Dysregulation of ureagenesis and glutaminolysis in DIAMONDTM mice played a major role in MASLD progression
15. THU-268 Differential transcriptomic profile in platelet-derived extracellular vesicles in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
16. Rituximab is a safe and effective alternative treatment for patients with autoimmune hepatitis: Results from the ColHai registry
17. aProceedings of the 5th Meeting of Translational Hepatology, organized by the Spanish Association for the Study of the Liver (AEEH)
18. Enfermedad de Wilson
19. Clinical application of Magnetic resonance elastography in hepatocellular carcinoma: from diagnosis to prognosis
20. Consenso AEEH «Consenso sobre métodos de detección y derivación de enfermedades hepáticas prevalentes ocultas»
21. General Overview About the Current Management of Nonalcoholic Fatty Liver Disease
22. Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD
23. Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis
24. Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH)
25. Bone morphogenetic protein 2 is a new molecular target linked to non-alcoholic fatty liver disease with potential value as non-invasive screening tool
26. Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation
27. Derivation and validation of the nonalcoholic fatty liver disease cirrhosis score (NCS) to distinguish bridging fibrosis from cirrhosis
28. Novel insights into metabolic‐associated steatotic liver disease preclinical models
29. Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease
30. The Spectrum of NAFLD: From the Organ to the System
31. Circular RNAs in non-alcoholic fatty liver disease: Functions and clinical significance
32. Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease
33. Impact of liver injury on the severity of COVID-19: a systematic review with meta-analysis
34. Stratification of patients in NASH clinical trials: A pitfall for trial success
35. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH
36. Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis
37. Corrigendum to “Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosis” [J Hepatol 79(4) (2023 Oct) 967–976]
38. Prognostication in Advanced Chronic Liver Disease Using Liver Stiffness Measurement: Repetita Iuvant
39. P18 Glutaminolysis and Steatosis to Steatohepatitis Transition: Role of Glutaminase
40. Inflammatory Bowel Disease Is an Independent Risk Factor for Metabolic Dysfunction–Associated Steatotic Liver Disease in Lean Individuals
41. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis
42. Calidad de vida en los pacientes con hepatitis C. Importancia del tratamiento
43. COVID-19 and the digestive system: protection and management during the SARS-CoV-2 pandemic
44. Looking for a new name for non-alcoholic fatty liver disease in Spanish: esteatosis hepatica metabolica (EHmet)
45. miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis
46. Peer-to-Peer Sessions in Primary Care to Improve the Hepatitis B Detection Rate in Seville, Spain
47. Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)
48. Impact of the metabolic profile on the response to ursodeoxycholic acid in patients with primary biliary cholangitis: results of the ColHai registry
49. Main clinical characteristics and evolutionary events among patients suffering Wilson disease in Spain: first results from the Spanish Wilson registry
50. Analysis of the diagnostic accuracy of the non-invasive fibrosis indices NFS, HFS, and FIB-4 in the staging of advanced fibrosis in patients with metabolic fatty liver: meta-analysis of comparative studies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.